Anas Platyrhynchos Feather Anser Anser Feather Bos

證據等級: L5

預測適應症: 0 個

Animal Allergen Multi-Panel Extract: No TxGNN Repurposing Prediction Generated

One-Sentence Summary

This product is a 15-component allergen extract mixture — comprising 14 animal-derived allergens (duck feather, goose feather, cat hair, dog hair, horse dander, rabbit skin, and others) plus histamine dihydrochloride as a positive control — characteristic of allergy skin-testing panels used in clinical allergy diagnosis and immunotherapy. No TxGNN repurposing predictions were generated for this product, as no DrugBank ID could be assigned and the product has no registered indications in either Taiwan or the US market. Without a predicted indication or supporting evidence, a standard drug repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	None registered
Predicted New Indication	None generated
TxGNN Prediction Score	Not available
Evidence Level	L5 — model produced no output
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

What Is This Product?

This entry does not correspond to a single pharmaceutical agent. The INN field contains a semicolon-separated list of 15 biological allergen components:

Component	Source Species	Material Type
ANAS PLATYRHYNCHOS FEATHER	Mallard duck	Feather
ANSER ANSER FEATHER	Goose	Feather
BOS TAURUS HAIR	Cattle	Hair
CANIS LUPUS FAMILIARIS HAIR	Dog	Hair
CAVIA PORCELLUS HAIR	Guinea pig	Hair
EQUUS CABALLUS DANDER	Horse	Dander
EQUUS CABALLUS HAIR	Horse	Hair
FELIS CATUS HAIR	Cat	Hair
GALLUS GALLUS FEATHER	Chicken	Feather
HISTAMINE DIHYDROCHLORIDE	—	Positive control
MESOCRICETUS AURATUS SKIN	Hamster	Skin
MUS MUSCULUS HAIR	Mouse	Hair
ORYCTOLAGUS CUNICULUS HAIR	Rabbit	Hair
ORYCTOLAGUS CUNICULUS SKIN	Rabbit	Skin
SUS SCROFA HAIR	Pig	Hair

This configuration — multiple animal hair/feather/dander allergens combined with histamine dihydrochloride — is typical of an allergy skin prick test (SPT) panel or an allergen-specific immunotherapy (AIT) preparation used to diagnose and manage allergic sensitisation to animal-derived allergens.

The TxGNN model requires a single drug entity mapped to a DrugBank node. Because this product is a complex multi-allergen mixture with no DrugBank ID (null) and no single pharmacological mechanism of action, the prediction pipeline produced no output.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This product cannot be evaluated under the standard TxGNN drug repurposing framework because it is a multi-allergen diagnostic/therapeutic mixture with no DrugBank mapping, no approved indication on record, and no US market registration — the model produced zero predictions.

To proceed, the following is needed:

Clarify the intended drug entity: Identify which single active component (e.g., a specific allergen extract or histamine dihydrochloride) should be the subject of a repurposing query, and obtain its DrugBank ID
Resolve data gap DG001: Download the TFDA package insert PDF to extract safety warnings and contraindications
Resolve data gap DG002: Query DrugBank API for mechanism-of-action data for the relevant active component
Re-run TxGNN: After establishing a valid drug–DrugBank ID mapping, re-submit as a single-entity prediction request
Confirm product category: Determine whether this is a diagnostic allergen panel (in vitro or skin test) or an immunotherapy product, as the regulatory and clinical pathway differs substantially between the two
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.